Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety,Tolerability, and Pharmacokinetics of 3 g of Ceftolozane/Tazobactam in Healthy Adults:A Randomized, Placebo-Controlled, Multiple-Dose Study

Trial Profile

Safety,Tolerability, and Pharmacokinetics of 3 g of Ceftolozane/Tazobactam in Healthy Adults:A Randomized, Placebo-Controlled, Multiple-Dose Study

Completed
Phase of Trial: Phase I

Latest Information Update: 24 May 2018

At a glance

  • Drugs Ceftazidime/tazobactam (Primary)
  • Indications Gram-negative infections; Intra-abdominal infections; Nosocomial pneumonia; Pyelonephritis; Urinary tract infections
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 24 May 2018 New trial record
    • 01 May 2018 Results published in the Clinical Pharmacology in Drug Development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top